Russia’s𒐪 pharma and healthcare sector holds sig🍎nificant growth potential, stemming from the country’s large and aging p♑opulation. Russia is home to largest pharmaceutical market 🥀in Central and Eastern Europe and is a key emerging market f༒or multinational pharmaceutical majors. The sector of hea🐎lthcare and social work activities generated 3.1% of the Russian GDPꦓ in 2019 and empl🐽oyed 7.9% of the country’s workforce. In 2019, total healthcare spending amounted to RUB 5.7tn, equivalent to 5.2% of nominal GDP, wit🎉h the government taking the lion&ജrs♒quo;s share of 58%. The country is a net importer of pharmaceutical products. Multinational pharma groups dominate the domestic drug and medical equipment market but local producers have gained market share in&🐟nbsp;recent years, taking advantage of supportive governmꦏent policy and the depreciation of the rouble. ​

This report provides a complete and detailed analysis of the pharma and healthcare sector for Russia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a 𒈔balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the pharma and healthcare sector in Russia
• Access forecasts for growth in the sector
• View key data on healthcare spending and health insurance in Russia
• Crystallise the forces both driving and restraining this sector in Russia
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Russia
• Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels).

See below for 🎃a complete table of report contents: